本篇是再鼎医药2026 ACAAI 投资者会议英文纪要及中文翻译,内容包含再鼎医药研发负责人Rafael对ZL1503一期健康志愿者数据的解读以及Q&A环节。Zai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans Transcript
Nov 13, 2026, 11:39 AM ETZai Lab Limited (ZLAB) Stock
Zai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans November 13, 2026 8:00 AM EST
Company Participants
Rafael Amado - President and Head of Global Research & Development
Conference Call Participants
Li Wang Watsek - Cantor Fitzgerald & Co., Research DivisionDaina Graybosch - Leerink Partners LLC, Research DivisionKaiyue Yang - UBS Investment Bank, Research DivisionYigal Nochomovitz - Citigroup Inc., Research DivisionDiogo Teles
Presentation
Operator
Hello, ladies and gentlemen. Thank you for standing by and welcome to Zai Lab's 2026 ACAAI Investor Call. [Operator Instructions] As a reminder, today's call is being recorded. It is now my pleasure to turn the floor over to Rafael Amado, President and Head of Research and Development of Zai Lab. Please go ahead, sir.
Rafael AmadoPresident and Head of Global Research & Development
Good morning, everyone. Thank you for joining us today. My name is Rafael Amado, and I am President and Head of Research and Development for Zai Lab.
Later this afternoon at the American Academy of Allergy, Asthma and Immunology Annual Meeting, we will be presenting the first clinical data for ZL-1503, our internally discovered long-acting bispecific antibody that blocks both IL-13 cytokine ligand and IL-31 receptor alpha.
We went into the Phase I/Ib study with clear questions about safety, half-life and target engagement. ZL-1503 met every objective that we tested in this healthy volunteer study. The study continues with further follow-up and multiple ascending doses in patients with atopic dermatitis. This MAD data will be available in the first half of next year.
Our forward-looking statements are on slide 2.
Moving to today's agenda, I'll walk through the highlights of our presentation at the conference and what it means for the program. And then I'll open up for questions and answers.
Briefly for context on our global R&D programs, ZL-1503 is our leading immunology program. Zoci, our DLL3 antibody-drug conjugate, is our lead oncology program with registrational data in extrapulmonary neuroendocrine carcinomas and small cell lung cancer next year, setting us up for our first potential U.S. submission next year.
Other global oncology programs are listed, included an additional ADC currently in Phase I, a T-cell engager and immunocytokine, both in IND-enabling studies for INDs in December of this year and the first quarter of next year, respectively. Today, though, the focus is entirely on ZL-1503.
Therapies for atopic dermatitis are evaluated across key attributes: lesion control, itch relief, dosing convenience and safety. We designed the Phase I plus Ib program to test ZL-1503 across each one of these attributes. Here is what the healthy volunteer dataset showed us.
On IL-13 blockade, a single dose of ZL-1503 produced at least 90% inhibition of pSTAT or phospho-STAT through at least week 12 at 200, 600 and 1,000 milligrams in peripheral blood. We are seeing strong IL-13 pathway inhibition.
Second, dosing. The mean terminal half-life was approximately 40 to 50 days with dose-proportional exposure. This supports the potential for extended dosing in maintenance.
Third, safety. There were no serious adverse events, no dose-limiting toxicities and no anti-drug antibodies detected as of the data cutoff.
The fourth question, itch, needs data from patients with atopic dermatitis, which we plan to present next year. That said, we have already shown compelling preclinical data demonstrating IL-31 receptor alpha blockade comparable to nemolizumab in vitro and sustained itch suppression for up to 112 days in non-human primates and a transgenic murine model.
On the next slide, I want to explain why itch matters so much in atopic dermatitis, and why we designed ZL-1503 to target it directly. Itch is among the most distressing symptoms for this disease. More than half of adults with atopic dermatitis name it as the most burdensome symptom, nearly 3/4 of patients with more extensive disease report severe itch in the previous week, and more than 90% report moderate to severe sleep disturbance.
Overall, severe atopic dermatitis has an enormous impact on health-related quality of life, comparable or worse in some domains to chronic conditions such as heart disease or diabetes, according to peer-reviewed journals. Itch also contributes to the disease.
Itching leads to scratching, scratching disrupts the skin barrier, allergens and irritants penetrate the skin and inflammation can be perpetuated, preventing pruritus improvement.
Next slide. ZL-1503 targets two clinically validated pathways. IL-13 drives the inflammatory cascade through Th2 differentiation, eosinophil and mast cell activity and IgE production. IL-31 signaling through IL-31 receptor alpha activates sensory nerves that drive itch. IL-4 receptor alpha blockade can increase IL-4 and can also alter Th2/Th1 balance, leading to a degree of autoimmune dysregulation. IL-4 tends to be lesional in the skin while IL-13 is diffusely distributed. The biology is proven. The question is whether one molecule can hit both cleanly with less frequent dosing. We think ZL-1503 can. ZL-1503 is a full IgG antibody against IL-13 with a single-domain VHH targeting IL-31 receptor alpha fused to the N-terminus of the light chain of anti-IL-13 antibody. The molecule is 171 kilodaltons.
The Fc region carry leucine replacement with alanine double mutations to reduce effector function, and YTE mutations to extend serum half-life, supporting the potential for longer dosing intervals. But clinically, ZL-1503 strongly inhibited both IL-13 and IL-31 signaling and had a favorable safety profile.
Turning to itch, because IL-31-driven itch can't be measured in healthy volunteers, I wanted to share our data with our preclinical models. We tested both arms in non-human primates.
A single intravenous dose produced dose-dependent suppression of monkey IL-31-induced scratching. That left panel shows PK showing dose-dependent exposure. And on the right panel, we see at 10 milligrams per kilogram, one dose suppressed scratching through day 112, counted utilizing artificial intelligence.
Duration of inhibition tracked exposure, so we saw a clear PK/PD relationship. This preclinical data gives us confidence that ZL-1503 can deliver meaningful itch relief. We look forward to sharing the first data in patients with atopic dermatitis, and now for the clinical data.
Turning to our clinical program, ZL-1503-001 is a global randomized double-blind placebo-controlled Phase I/Ib study. The study has two parts. Part A, the single ascending dose portion we're presenting today, enrolled 48 healthy volunteers across 6 cohorts, randomized 6:2 to ZL-1503 or placebo in each cohort at intravenous doses from 50 milligrams to 1,000 milligrams. The primary endpoint is safety with PK and immunogenicity as secondary endpoints and phospho-STAT, TARC, CCL26 and IgE as pharmacodynamic biomarkers.
Part B is a multiple ascending dose study in patients with moderate to severe atopic dermatitis. Two cohorts are included of 12 and 24 patients in two intravenous ascending doses. Alongside safety, PK and biomarkers, it measures efficacy, lesion control by EASI and IGA, itch and sleep.
On the next slide, baseline characteristics were generally balanced across cohorts. The majority of participants were Caucasian or Asian. All healthy volunteer cohorts 600 milligrams and 1,000 milligrams included twice as many patients as they were done as separate cohorts in China in addition to New Zealand.
Moving to safety, ZL-1503 was well tolerated across all doses up to 1,000 milligrams. There were no serious adverse events, no dose-limiting toxicities and no adverse events leading to treatment interruption.
There was a single Grade 3 TEAE in a placebo participant. Otherwise, toxicity was mostly related to injection site complaints. There were no Grade 3 or higher treatment-emergent adverse events on ZL-1503 dosed participants. Most frequently, adverse events were mild and related to study procedures such as bruising from blood draws.
Next slide. Exposure increased proportionally with dose from 50 to 1,000 milligrams, and the mean terminal half-life was approximately 40 to 50 days across all doses, about twice the published half-lives of approved IL-4, IL-13 and IL-31 receptor antibodies.
PK was consistent with our Chinese and New Zealand cohorts at 600 and 1,000 milligrams. Importantly, no anti-drug antibodies were detected as of the data cutoff across all dosed ZL-1503 participants.
So in summary; first, the YTE half-life extension prolongs exposure in humans: second, dose-proportional PK profile gives us a reliable basis for modeling regimens from 50 to 1,000 milligrams; and third, the absence of detectable anti-drug antibodies is encouraging as we move towards repeat dosing.
Ultimately, our goal is to identify a regimen that can provide both lesion control and rapid and sustained itch relief with less frequent dosing.
Next slide. We assessed IL-13 pathway inhibition with four biomarkers. phospho-STAT is the most direct. Inhibition of IL-13-stimulated STAT phosphorylation shows that pathway is blocked. TARC and CCL26 are downstream chemokines that reflect type 2 helper cell-mediated inflammation. And IgE is a broader marker of type 2 immune activity. These biomarkers help show whether ZL-1503 engages its target and suppresses the downstream signaling that drives disease.
On phospho-STAT, a single dose of ZL-1503 produced rapid, near-complete inhibition of IL-13-stimulated phospho-STAT. Inhibition was evident in the first post-dose measurement at 200, 600 and 1,000 milligrams, and it was 90% or greater through week 12. phospho-STAT was not measured between weeks 12 and 24. The 1,000-milligram week 24 result wasn't available at the data cutoff.
The duration of inhibition was dose-dependent, consistent with the PK that we just saw. The results show durable blockade of the IL-13 pathway, supporting the potential for extended dosing intervals.
ZL-1503 also reduced TARC, or thymus-activation-regulated chemokine, also known as CCL17. TARC is a downstream chemokine associated with atopic dermatitis severity produced by skin cells, dendritic cells and endothelial cells that attract T helper cells to inflamed skin during the acute phase of atopic dermatitis.
Single doses reduced circulating TARC across dose levels comparable to what's been reported with dupilumab. TARC levels are low in these healthy volunteers, but in spite of that, we see meaningful TARC suppression.
Beyond TARC, ZL-1503 reduced CCL26, an IL-13-inducible chemokine linked to eosinophil recruitment. Reductions of 20% to 30% appeared within the first week across all active doses while placebo remained flat, and they persisted through week 24.
We also saw an early trend towards IgE at higher doses. IgE declined slowly because of its long half-life. So longer follow-up and data in patients with atopic dermatitis will give us a clearer picture.
So in summary, phospho-STAT, TARC and CCL26 show that ZL-1503 inhibits IL-13 signaling and its downstream effects, which transcends beyond the time of IC90 for phospho-STAT suppression in the case of CCL26 and IgE.
So what does this mean for patients? Today's patients face trade-offs. IL-13 and IL-4 receptor antibodies provide strong lesion control, but itch relief takes longer. Nemolizumab provides rapid itch relief with more modest lesion control. JAK inhibitors offer both, but carry a box warning.
ZL-1503 is designed to remove those trade-offs. Lesion control is in line with the IL-13 class, rapid itch relief through IL-31 receptor alpha blockade. We believe that comprehensively interrupting the itch-scratch-inflammation cycle has the potential to translate into best-in-class results for patients.
Furthermore, on dosing, patients on dupilumab inject 26 times a year; lebrikizumab and nemolizumab maintenance is between 7 and 13. ZL-1503 has a half-life that is 2x at least approved agents and phospho-STAT inhibition that holds for months.
ZL-1503 has the potential for maintenance dosing every 3 months or more, equating to about 4 injections a year after induction treatment. That's a reduction of up to 80% versus every-two-week dosing, with meaningful control of inflammation in line with dupilumab and lebrikizumab and rapid and persistent control of pruritus commensurate with nemolizumab.
We see Q3 months as the optimal dosing schedule. Beyond that, the added convenience matters less. However, the final interval will be set by repeat-dose data in patients and tested in Phase IIb with the subcutaneous formulation.
Lastly, ZL-1503 has demonstrated good safety. Taken together, we believe 1503 has a profile that can be highly differentiated in this market.
Now looking ahead, 2027 is an important year of catalysts. In the first half of 2027, we expect the first data in patients with atopic dermatitis from the multiple ascending placebo-controlled dose part of the Phase I/Ib study, including PK, PD, lesion control and itch.
Our IV to subcutaneous bridging study is now fully enrolled, and we expect data in the first half of the year. Together, this data will guide dose and regimen selection for a global Phase IIb study that we plan to initiate in 2027 using an already available subcutaneous formulation. We look forward to sharing updated data on this program throughout the year.
And with that, I'll open it up for questions.
Question-and-Answer Session
Operator
[Operator Instructions] And our first question comes from Li Watsek from Cantor.
Li Wang WatsekCantor Fitzgerald & Co., Research Division
Congrats on the great data. Just given the 40-day half-life with IV formulation, how should we think about the translation all the way through to the subcu? And what is your confidence level for Q2-month or Q3-month dosing regimen?
Rafael AmadoPresident and Head of Global Research & Development
Thank you for the question. So as I said before, we have a very high-yield subcu formulation that is ready for the clinic, and we finished the bioequivalency study between IV and subcu. So those data are still to be analyzed, but we don't expect any changes in the subcutaneous formulation with regards to half-life. I think because of the high-yield, it will allow us to test high doses. And like other products, it will probably consist on a regimen of short induction followed by Q3 month dosing. That's what we expect.
Most of these products have either autoinjectors or prefilled syringes and they end up injecting in two different sites to give the upper dose. We don't yet know whether we will be able to just inject once or twice. That's what the Phase IIb study is for. But we will learn a lot, I think, from the IV because we don't think there will be very many differences.
We've already started to think about modeling. And of course we need some assumptions with regards to absorption of the subcutaneous formulation to be able to do that. We want to be above concentrations of lebri and some of the existing products, but we're very confident that after a short period of induction, Q3 months should be viable.
Operator
Our next question comes from Daina Graybosch from Leerink Partners.
Daina GrayboschLeerink Partners LLC, Research Division
Congrats on the great data. I wonder, Rafael, if you could talk about the design, the format, and what in the format you think is leading to the two really promising aspects, both the long PK, so you're not getting a lot of receptor-mediated rapid clearance, and the lack of ADAs?
Rafael AmadoPresident and Head of Global Research & Development
Yes, good question. I think there may be some TMDD initially, but it's mild. The other thing I would say is that in all the products that have been tested before, the PK in healthy volunteers and atopic dermatitis tends to be very similar. So we do not expect dramatic changes in the PK in the MAD portion of the study. It just doesn't seem to be a very immunogenic product.
I mean, there are a lot of examples of single injection leading to anti-drug antibodies. Not all of them are neutralizing. And some of the products that are under development are engendering ADAs so far not affecting the PK as far as I know. But we're not seeing that looking with a very sensitive bioluminescence assay. And we're looking at both idiotypes, 13 and 31.
I think it's because of the humanization and also it's just a single VHH region for IL-31 blockade receptor alpha, which is pretty small. So the molecule is fully humanized. We obviously need to wait for the repeat dosing, but so far, we haven't seen anything. We did see something in animals, but that is very common and that never predicts what would happen in humans. So fingers crossed that the MAD data will show us the same type of clean results that we're seeing now.
Operator
Our next question and our next question comes from Michael Yee from UBS Securities.
Kaiyue YangUBS Investment Bank, Research Division
This is Kaiyue Yang for Michael Yee. Just a quick one for us, perhaps on the upcoming MAD data in atopic dermatitis patients, could you talk about the study design in terms of the size of the trial, the endpoints you're going to measure? And also, what is your expectation for the efficacy readout? And also, what is the timeframe of the study? Is it 4-week or a 12-week study?
Rafael AmadoPresident and Head of Global Research & Development
Yes, thanks for the question. So the MAD will enroll 36 patients with moderate to severe atopic dermatitis. There will be -- it's a randomized double-blind placebo-controlled study, 3:1 ZL-1503 to placebo in two different cohorts. So each cohort will study a dose -- a different dose. So we're honing into two different doses intravenously. The second cohort will have more patients than the first cohort.
In terms of what we're looking at, it will be the list of endpoints that you just saw, safety being even more important because these are patients. And then we will look at variable IgA AD scores, the various EASI scores, including 75 and 90, which equates very similarly to IgA. Importantly, we will look at pruritus with the PP-NRS score and sleep disturbances and other elements of quality of life and elements of inflammation such as eczema measurement. So it will be sort of a full assessment of efficacy. The patients will be taken out to week 16. The treatment will be early on and then we will measure effect out to week 16.
In terms of timing, we think we've already accrued to the first cohort and we'll get results on the two cohorts in the first half of next year and should be able to report during that time. I don't know if I missed any component of your question, but I hope that was comprehensive enough.
Kaiyue YangUBS Investment Bank, Research Division
That was clear. And in terms of doses, how many induction doses are there?
Rafael AmadoPresident and Head of Global Research & Development
Induction doses are 3 doses, and we don't treat long-term. So there will be some distinctions from some of the other competitors that you may have seen where they dose at week 12 for instance, and they've dosed at higher doses. There is a dose response in this disease up to a point where the results become more asymptotic, but we will dose more often and even week 12 to week 16, and we will explore variabilities on dosing until we get to the maintenance setting, which we want to get to very quickly in Phase IIb. But early on in this study, we're only giving 3 doses and wait until week 16.
Operator
And our next question comes from the line of Yigal Nochomovitz from Citigroup.
Yigal NochomovitzCitigroup Inc., Research Division
I just had a few here on the PK/PD. With regard to the measurement of the IL-13 cytokine and IL-31, obviously I know these are healthy volunteers, but nonetheless, were you able to measure free IL-13 in plasma, which obviously would go down, and then free IL-31 which I would think would maybe go up since you're blocking the receptor? That's one question.
And then the other one is, it looks like from the PK/PD, over 200 milligrams, it seems like pSTAT6 is kind of at the assay ceiling. So just wondering as far as how you would identify a minimal useful exposure considering it looks like you're getting pretty good blockade at over 200?
Rafael AmadoPresident and Head of Global Research & Development
Yes, very good questions. We did not look at IL-13, 31 in these healthy volunteers. I actually would imagine the levels are low, but it may be a better grade loop on IL-31 going up. We definitely know that in IL-4 when it's blocked, IL-4 cytokine does go up. But it is an interesting question and I'll bring it up to see whether we can do exploratory assays to look at this.
I think we've also started with 6 where we're pretty pleased to see this long-term inhibition. It's not even clear that IC90 is the right level and whether there's -- it really correlates well with disease control. You can see that some of the pharmacodynamic endpoints actually lag after phospho-STAT inhibition and that would make sense. And so we obviously aim to have that below the IC90 for as long as possible.
The only other thing I would say is that we didn't measure, as I said in the prepared remarks, between 12 and 16 and 24. So we just extrapolated and carried it forward, but it's possible that it may have remained suppressed out to a few more weeks before it went up by 20% at week 24. So hopefully this answers your questions, but we were very pleased that these relatively few doses were able to control IL-13 and STAT6 phosphorylation, which I think most people in the field believe that hitting that hard early on during induction is important.
Yigal NochomovitzCitigroup Inc., Research Division
And then just one quick follow-up. So the 90% greater than -- hitting the pSTAT6 inhibition at week 12, was that every patient that got that or that's the -- is that the average?
Rafael AmadoPresident and Head of Global Research & Development
Yes, that's the average of pretty much every patient got it.
Operator
[Operator Instructions] And our next question comes from the line of Anupam Rama from JPMorgan.
Diogo Teles
Hi, this is Diogo Teles for Anupam Rama at JPMorgan. Based on today's healthy volunteer data, we have a couple of questions on itch in your atopic dermatitis patients. From a patient perspective, what is the importance of itch? And how do you see differentiation from competitors in the space?
Rafael AmadoPresident and Head of Global Research & Development
Yes, I love this question because eczema or atopic dermatitis is viewed as a skin condition, but it's more than a skin condition. And many -- the goal of many dermatologists is to get rid of pruritus because it is incredibly distressing to patients. They can cover the lesions, but they cannot stop scratching. And when it is in children, the entire family suffers a tremendous burden. There is not just the potential for superinfections in the lesion that happens with Staph aureus, exposure to allergens and delays in healing the inflammation. But the patient is -- and actually the regulators have recognized this have an impact in neurocognitive scales. So a number of these scales need to be employed to be measured to develop these drugs; depression, suicidality and other scales of how quality of life is manifested by pruritus. So it is a paramount symptom to control, which we look forward to seeing how it works in the MAD.
Eventually when the inflammation goes away, pruritus subsides. But the important thing that we're trying to bring in with this dual inhibitor is immediate abrogation of pruritus on days 1 and 2, at least a 4-point drop in the PP-NRS scale, which is clinically significant. And so we're looking forward to seeing what the MAD data tells us about that.
Operator
[Operator Instructions] I'm showing no further questions. I'll now turn the conference back to Rafael for his closing comments.
Rafael AmadoPresident and Head of Global Research & Development
Thank you so much all of you for joining us this morning. I look forward to providing further updates next year, hopefully in the first half of the year. And operator, you may now disconnect.
Operator
Thank you for your participation in today's conference. This does conclude the program. You may now disconnect your lines.
//中文版Zai Lab Limited(ZLAB)讨论ZL-1503第一阶段数据及特应性皮炎发展计划文字稿
2026年11月13日,东部时间上午11:39Zai Lab Limited (ZLAB)股票
Zai Lab Limited(ZLAB)讨论ZL-1503第一阶段数据及特应性皮炎开发计划 2026年11月13日 美国东部时间上午8:00
公司参与者
拉斐尔·阿马多 - 总裁兼全球研发主管
电话会议参与者
李王华卓 - 康托尔·菲茨杰拉德公司,研究部黛娜 格雷博施 - Leerink Partners LLC,研究部杨凯月——瑞银投资银行研究部伊加尔 诺霍莫维茨 - 花旗集团研究部迪奥戈·特莱斯
表现
操作员
女士们,先生们,大家好。感谢大家的等待,欢迎收听Zai Lab 2026年ACAAI投资者电话会议。[接线员说明]提醒一下,今天的电话会议正在录音。现在我很荣幸将发言权交给Zai Lab的总裁兼研发主管Rafael Amado。请继续,先生。
拉斐尔·阿马多全球研发总裁兼负责人
大家早上好。感谢大家今天的到来。我叫拉斐尔·阿马多,是Zai实验室的总裁兼研发主管。
今天下午晚些时候,在美国过敏、哮喘与免疫学会年会上,我们将展示ZL-1503的首批临床数据,ZL-1503是一种我们内部发现的长效双特异性抗体,能够阻断IL-13细胞因子配体和IL-31受体α。
我们带着关于安全性、半衰期和靶点结合度的明确问题进入了I/Ib期临床试验。ZL-1503满足了我们这项健康志愿者研究中测试的所有目标。研究将继续进行进一步随访,并对特应性皮炎患者进行多次递增剂量。这些MAD数据将在明年上半年发布。
我们的前瞻性陈述见第2页幻灯片。
进入今天议程,我将介绍我们在会议上的演讲亮点及其对项目的意义。然后我将开放提问与回答。
简要介绍我们的全球研发项目背景,ZL-1503是我们领先的免疫学项目。Zoci,我们的DLL3抗体-药物偶联物,是我们的主导肿瘤项目,明年将注册肺外神经内分泌癌和小细胞肺癌,为明年首次美国提交项目奠定基础。
其他全球肿瘤学项目也被列举,包括目前处于一期阶段的额外ADC、T细胞增殖剂和免疫细胞因子,这两个项目分别于今年12月和明年第一季度参与IND的IND赋能研究。不过,目前的重点完全放在ZL-1503上。
特应性皮炎的治疗在关键属性上进行评估:病灶控制、缓解瘙痒、用药便利性和安全性。我们设计了第一期加Ib项目,以测试ZL-1503在这些属性中的每一项。以下是健康志愿者数据集显示的内容。
在IL-13阻断剂中,单剂量ZL-1503在外周血中200、600和1000毫克时,至少能抑制pSTAT或磷酸STAT90%以上。我们观察到IL-13通路抑制效果显著。
其次,剂量。平均末端半衰期约为40至50天,剂量比例暴露。这支持了维持剂量延长的潜力。
第三,安全性。截至数据截止期,未检测到严重不良事件、剂量限制性毒性,也未检测到抗药抗体。
第四个问题“瘙痒”需要来自特应性皮炎患者的数据,我们计划明年公布。尽管如此,我们已经展示了令人信服的临床前数据,证明IL-31受体α阻断效果可与体外奈莫珠单抗相当,并在非人灵长类动物和转基因小鼠模型中持续抑制瘙痒长达112天。
在下一张幻灯片中,我想解释为什么瘙痒在特应性皮炎中如此重要,以及为什么我们设计ZL-1503是直接针对瘙痒的。瘙痒是该病最令人痛苦的症状之一。超过一半的成人特应性皮炎患者将其列为最沉重的症状,近四分之三病情较为严重的患者报告前一周出现严重瘙痒,超过90%报告中度至重度睡眠障碍。
总体而言,重度特应性皮炎对健康相关生活质量有巨大影响,在某些领域与心脏病或糖尿病等慢性疾病相当甚至更严重,同行评审期刊指出。瘙痒也加重了该病。
瘙痒会导致抓挠,抓挠会破坏皮肤屏障,过敏原和刺激物会渗透皮肤,炎症会持续,从而阻碍瘙痒的改善。
下一张幻灯片。ZL-1503靶向两条临床验证的通路。IL-13通过Th2分化、嗜酸性粒细胞和肥大细胞活性以及IgE生成驱动炎症级联反应。IL-31通过IL-31受体α激活驱动瘙痒的感觉神经。IL-4受体α阻断可以增加IL-4,并可能改变Th2/Th1的平衡,导致一定程度的自身免疫失调。IL-4在皮肤中多为病变,而IL-13则分布广泛。生物学原理已被证实。问题在于单一分子是否能以较低剂量干净地同时作用两者。我们认为ZL-1503可以。ZL-1503是一种针对IL-13的完整IgG抗体,具有单域VHH靶向IL-31受体α,融合在抗IL-13抗体轻链的N端。该分子的重量为171千道尔顿。
Fc区携带带丙氨酸双突变的亮氨酸替代以降低效应器功能,并携带YTE突变以延长血清半衰期,支持延长给药间隔的潜力。但临床上,ZL-1503强烈抑制IL-13和IL-31信号,安全性良好。
说到瘙痒,因为IL-31驱动的瘙痒无法在健康志愿者中测量,我想将我们的数据与临床前模型分享。我们在非人灵长类动物中测试了这两类。
单次静脉注射可产生剂量依赖性抑制猴子IL-31引起的抓挠行为。左侧面板显示PK表现出剂量依赖性暴露。右侧面板显示,在10毫克每公斤时,通过人工智能计数,1剂量抑制抓挠行为持续到第112天。
抑制持续时间追踪暴露,因此我们看到了PK/PD的明确关系。这些临床前数据让我们有信心ZL-1503能够有效缓解瘙痒。我们期待分享首批特应性皮炎患者数据,现在将发布临床数据。
谈到我们的临床项目,ZL-1503-001是一项全球随机双盲安慰剂对照I/Ib期研究。该研究分为两部分。A部分,即我们今天呈现的单剂量递增部分,招募了48名健康志愿者,分布在6个队列中,每个队列以6:2的比例随机分配到ZL-1503或安慰剂,静脉注射剂量从50毫克到1000毫克不等。主要终点是安全性,其次以磷酸-STAT、TARC、CCL26和IgE为药效学生物标志物。
B部分是一项针对中重度特应性皮炎患者的多剂量递增研究。包含两个队列,分别为12名和24名患者,分别采用两次静脉递增剂量。除了安全性、PK和生物标志物外,还测量疗效、通过EASI和IGA控制病灶、瘙痒和睡眠。
下一张幻灯片中,基线特征在各队列间总体平衡。大多数参与者为白人或亚洲人。所有健康志愿者队列(600毫克和1000毫克)患者数量是中国及新西兰分组的两倍。
安全性方面,ZL-1503在1000毫克以内所有剂量均具有良好耐受性。未发生严重不良事件,无剂量限制毒性,也无导致治疗中断的不良事件。
安慰剂组中出现1例3级TEAE病例。其余毒性主要与注射部位抗议相关。ZL-1503剂量参与者未出现3级及以上治疗中出现的不良事件。多为轻度不良事件,且与抽血时出现瘀伤等研究程序相关。
下一张幻灯片。剂量从50毫克增加到1000毫克,暴露量会相应增加,所有剂量的平均末端半衰期约为40至50天,约为已批准IL-4、IL-13和IL-31受体抗体的两倍。
PK与我们中国和新西兰队列的600毫克和1000毫克一致。值得注意的是,截至数据截止时间,所有已服药ZL-1503参与者均未检测到抗药抗体。
总结一下;首先,YTE半衰期延长延长了人类暴露时间;其次,剂量比例的PK曲线为我们构建50至1000毫克的方案提供了可靠的基础;第三,缺乏可检测的抗药抗体在我们迈向重复剂量的过程中令人鼓舞。
最终,我们的目标是找到一种既能控制病灶又能快速持续缓解瘙痒的方案,同时减少用药频率。
下一张幻灯片。我们用四个生物标志物评估了IL-13通路的抑制效果。磷酸STAT是最直接的。抑制IL-13刺激的STAT磷酸化表明该通路被阻断。TARC和CCL26是下游趋化因子,反映2型辅助细胞介导的炎症。IgE是2型免疫活性的更广泛标志物。这些生物标志物有助于判断ZL-1503是否与其目标结合并抑制驱动疾病的下游信号。
在磷酸STAT中,单剂量ZL-1503能迅速且几乎完全抑制IL-13刺激的磷酸STAT。在首次剂量后测量中,抑制在200、600和1000毫克时明显,且在第12周时抑制率达到90%或以上。在第12至24周之间未测量磷酸STAT。第24周1000毫克结果在数据截止时尚未公布。
抑制持续时间与剂量相关,与我们刚才看到的药效一致。结果显示IL-13通路被持久阻断,支持延长剂量间隔的可能性。
ZL-1503还降低了TARC(胸腺激活调控趋化因子,也称为CCL17)。TARC是一种下游趋化因子,与特应性皮炎的严重程度相关,由皮肤细胞、树突状细胞和内皮细胞产生,这些细胞在特应性皮炎急性期吸引T辅助细胞到炎症皮肤。
单次剂量降低了循环中的TARC水平,剂量水平与dupilumab相当。这些健康志愿者的TARC水平较低,但尽管如此,我们仍看到有意义的TARC抑制。
除TARC外,ZL-1503还降低了CCL26,这是一种与嗜酸性粒细胞招募相关IL-13诱导的趋化因子。所有有效剂量在第一周内减少了20%至30%,而安慰剂组保持平稳,且持续至第24周。
我们也观察到高剂量时早期趋向IgE的趋势。由于IgE半衰期较长,下降缓慢。因此,更长的随访和特应性皮炎患者的数据将为我们提供更清晰的了解。
综上所述,磷酸STAT、TARC和CCL26表明ZL-1503抑制IL-13信号及其下游效应,这种作用在CCL26和IgE的抑制中超越IC90时间。
那么这对患者意味着什么?如今的患者面临权衡。IL-13和IL-4受体抗体提供强有力的病灶控制,但瘙痒缓解需要更长时间。奈莫利珠单抗能快速缓解瘙痒,病灶控制较为温和。JAK抑制剂同时提供两者,但带有警示框。
ZL-1503旨在消除这些权衡。病灶控制符合IL-13类,通过IL-31受体α阻断快速缓解瘙痒。我们相信,全面中断瘙痒-抓挠-炎症循环,有望为患者带来一流的治疗效果。
此外,剂量调整时,服用杜匹鲁单抗的患者每年注射26次;勒布基祖单抗和尼莫利珠单抗的维持时间在7至13次之间。ZL-1503的半衰期至少是获批药物的2倍,磷酸-STAT抑制作用可持续数月。
ZL-1503有潜力每3个月或更长时间维持一次,相当于诱导治疗后每年约4次注射。相比每两周一次,剂量可减少多达80%,且炎症控制与杜匹鲁单抗和勒布利祖单抗相匹配,瘙痒控制迅速持久,与奈莫利珠单抗相当。
我们认为Q3个月是最佳剂量安排。除此之外,便利性影响较小。不过,最终间隔将根据患者的重复剂量数据设定,并在皮下注射制剂的IIb期进行测试。
最后,ZL-1503展现了良好的安全性。综合来看,我们认为1503在该市场具有高度差异化的特点。
展望未来,2027年是一个重要的催化剂之年。我们预计在2027年上半年,第一期/Ib期研究中多重上升安慰剂对照剂量部分的特应性皮炎患者数据将发布,包括PK、PD、病灶控制和瘙痒。
我们的静脉至皮下桥接研究现已全面注册,预计今年上半年数据公布。这些数据将指导我们计划于2027年启动的全球IIb期临床试验的剂量和方案选择,该研究采用现有的皮下制剂。我们期待全年分享该项目的最新数据。
说到这里,我就开放提问了。
问答环节
操作员
[操作员说明]我们的第一个问题来自康托尔的李华采。
李王·瓦采坎托·菲茨杰拉德公司,研究部
恭喜你有这么棒的数据。考虑到静脉注射配方的半衰期为40天,我们应该如何看待从整个转化到胚胎的过程?你对第二季度或第三季度的给药方案信心水平如何?
拉斐尔·阿马多全球研发总裁兼负责人
感谢您的提问。正如我之前所说,我们已经有一种非常高产的subcu制剂,已经准备好用于临床,并且我们已经完成了静脉注射和皮下注射的生物等效性研究。这些数据还需要分析,但我们预计皮下制剂在半衰期方面不会有变化。我认为由于高产率,它将允许我们测试高剂量。和其他产品一样,它很可能是短剂量诱导,然后每3个月给药。这正是我们的预期。
大多数这些产品都配有自动注射器或预填充注射器,最终会在两个不同部位注射,以获得更高剂量。我们还不知道是否能仅注射一次或两次。这就是IIb期研究的目的。但我认为我们会从静脉注射中学到很多,因为我们认为差别不会太大。
我们已经开始考虑建模。当然,我们需要对皮下制剂的吸收做出一些假设,才能做到这一点。我们希望达到lebri和部分现有产品的浓度,但我们非常有信心,经过短时间的诱导,第三季度的吸收应该是可行的。
操作员
我们的下一个问题来自Leerink Partners的Daina Graybosch。
宋·格雷博斯Leerink Partners LLC,研究部
恭喜你有了很棒的数据。我想问问,Rafael,你能谈谈设计、格式,以及你认为在这种格式中,是什么导致了两个真正有前景的方面:长PK,也就是你没有获得太多受体介导的快速清除,以及缺乏ADA?
拉斐尔·阿马多全球研发总裁兼负责人
是的,好问题。我觉得一开始可能会有一些TMDD的症状,但很轻微。我还想说的是,在所有之前测试过的产品中,健康志愿者和特应性皮炎的PK通常非常相似。所以我们不预期在MAD部分的PK会有剧烈变化。它看起来并不是一个很强的免疫原性产品。
我的意思是,有很多单次注射导致抗药物抗体的例子。并非所有药物都能中和。据我所知,目前正在开发的一些产品正在产生抗性抗性抗药(ADA),但对PK没有影响。但我们用非常灵敏的生物发光检测法观察不到这种情况。我们同时观察了两个特型,13和31。
我认为这是因为人源化,而且IL-31受体受体α只有一个VHH区域,这个区域相当小。所以分子已经完全人源化了。我们显然需要等待重复剂量,但到目前为止,我们还没有看到任何异常。我们在动物身上确实看到了一些,但这非常常见,而且这从来无法预测人类会发生什么。所以希望MAD数据能给我们带来和现在一样干净的结果。
操作员
我们的下一个问题,来自瑞银证券的Michael Yee。
杨开月瑞银投资银行研究部
这里是杨凯月,采访的是Michael Yee。简单问一下,关于即将发布的特应性皮炎患者的MAD数据,您能谈谈试验设计、试验规模和将测量的终点吗?另外,您对疗效结果的预期是什么?还有,研究的时间框架是怎样的?是4周还是12周?
拉斐尔·阿马多全球研发总裁兼负责人
是的,谢谢你的提问。MAD将招募36名中度到重度特应性皮炎患者。这是一个随机双盲安慰剂对照研究,3:1 ZL-1503对安慰剂组,分为两个不同队列。每个队列会研究不同的剂量。我们正在通过静脉注射调整两种不同的剂量。第二组将比第一组患者更多。
就我们所关注的内容而言,将是你刚才看到的终点列表,安全性更为重要,因为这些都是患者。然后我们会查看不同的IgA AD评分,包括75和90的各种EASI评分,这与IgA非常相似。重要的是,我们会用PP-NRS评分来分析瘙痒,睡眠障碍以及其他生活质量因素和炎症因素,比如湿疹测量。这将是对疗效进行全面评估。患者将被安排到第16周。治疗会在早期进行,然后测量效果直到第16周。
关于时间安排,我们认为已经积累到了第一批,预计将在明年上半年获得两批队列的结果,届时应该能进行报告。我不知道我是否遗漏了你的问题中的哪些部分,但希望内容足够全面。
杨开月瑞银投资银行研究部
这很明确。关于剂量,有多少次诱导剂量?
拉斐尔·阿马多全球研发总裁兼负责人
诱导剂量是3次,我们不进行长期治疗。因此,你可能见过的其他竞争者会有一些区别,比如他们在第12周就给药,或者用更高剂量。这种疾病在某个阶段会有剂量反应,直到结果变得更无症状,但我们会更频繁地给药,甚至在第12周到第16周,并且会探索剂量的变异,直到进入维持阶段,我们希望在第二阶段b阶段尽快达到这个阶段。但在本研究早期,我们只给3次剂量,等待到第16周。
操作员
我们的下一个问题来自花旗集团的Yigal Nochomovitz。
伊加尔·诺霍莫维茨花旗集团,研究部
我刚在这里听到一些关于PK/PD的报告。关于IL-13细胞因子和IL-31的测量,显然我知道这些是健康的志愿者,但无论如何,你能不能在血浆中测量游离IL-13?它显然会下降,然后游离IL-31,我认为游离IL-31可能会上升,因为你阻断了受体?这是一个问题。
另一个问题是,从PK/PD来看,超过200毫克,pSTAT6似乎接近了测定上限。所以我想问,考虑到你在超过200毫克时似乎能得到相当不错的阻断,如何判断最小有用的暴露?
拉斐尔·阿马多全球研发总裁兼负责人
是的,非常好的问题。我们没有在这些健康志愿者中观察IL-13,31。我实际上认为IL-31的水平较低,但IL-31的等级循环可能更好。我们确实知道IL-4中阻断时,IL-4细胞因子会上升。但这是一个有趣的问题,我会提出来看看是否能做探索性检测来观察。
我认为我们也从第6个指标开始,我们对这种长期抑制效果感到非常满意。目前还不清楚IC90是否是正确的水平,以及它是否与疾病控制有很好的相关性。你可以看到,一些药理动力学终点实际上在磷酸-STAT抑制之后会滞后,这很合理。所以我们显然希望尽可能让IC90低于IC90。
我唯一想说的是,正如我在准备的发言中提到的,我们并没有测量12、16到24之间的数字。所以我们只是推算并继续推进,但有可能它在第24周时还会被抑制几周,直到24周时增加了20%。希望这能回答你的问题,但我们非常高兴,这些相对较少的剂量能够控制IL-13和STAT6磷酸化,我认为大多数领域人士认为在引产早期达到如此强烈的效果非常重要。
伊加尔·诺霍莫维茨花旗集团,研究部
然后就做了一次快速随访。所以在第12周达到pSTAT6抑制的90%是所有患者都达到了,还是平均值?
拉斐尔·阿马多全球研发总裁兼负责人
是的,这几乎是所有患者的平均感染率。
操作员
[操作员说明]接下来的问题来自摩根大通的阿努帕姆·拉玛。
迪奥戈·特莱斯
你好,我是摩根大通Anupam Rama的Diogo Teles。基于今天健康的志愿者数据,我们有几个关于特应性皮炎患者瘙痒的问题。从患者的角度来看,瘙痒的重要性是什么?你如何看待与该领域的竞争者之间的差异?
拉斐尔·阿马多全球研发总裁兼负责人
是的,我很喜欢这个问题,因为湿疹或特应性皮炎被视为一种皮肤病,但它不仅仅是皮肤病。许多皮肤科医生的目标是消除瘙痒,因为瘙痒对患者来说极其痛苦。他们可以覆盖病灶,但无法停止抓挠。当疼痛发生在儿童身上时,整个家庭都会承受巨大的负担。不仅仅是金黄色葡萄球菌感染时可能出现的超级感染、过敏原暴露以及炎症愈合延迟。患者本身——实际上监管机构也认识到这会影响神经认知量表。因此需要采用多种量表来衡量这些药物;抑郁症、自杀倾向以及瘙痒症对生活质量表现的其他影响。因此,这是必须控制的首要症状,我们期待看到它在MAD中的效果。
炎症消退后,瘙痒也会消退。但我们通过这种双重抑制剂,最重要的是在第1天和第2天立即消除瘙痒,PP-NRS评分至少下降4个百分点,这在临床上具有显著意义。因此,我们期待看到MAD数据对此的揭示。
操作员
[操作员说明]我没有其他问题。现在我把会议交回给拉斐尔,请他做结语。
拉斐尔·阿马多全球研发总裁兼负责人
非常感谢大家今天早上加入我们的节目。我期待明年能提供更多更新,希望能在上半年。接线员,您现在可以断开连接了。
操作员
感谢您参加今天的会议。节目到此结束。您现在可以断开线路了。